Assessment of objective visual function following idebenone administration in patients with leber hereditary optic neuropathy
- PMID: 38967874
- DOI: 10.1007/s10384-024-01077-z
Assessment of objective visual function following idebenone administration in patients with leber hereditary optic neuropathy
Abstract
Purpose: To objectively assess visual function in Leber's Hereditary Optic Neuropathy (LHON) patients; this study evaluated pre- and post-idebenone treatment changes in primary visual cortical (V1) responses using functional magnetic resonance imaging (fMRI), given the challenges in subjective testing due to central retinal ganglion cell damage.
Study design: A descriptive study involving four confirmed LHON patients.
Methods: Four patients received 900 mg/day of oral idebenone for 24 weeks. Baseline and post-treatment visual acuity, visual fields, and BOLD fMRI responses while passively viewed drifting contrast pattern visual stimuli were compared with self-reported symptoms.
Results: Post-idebenone, one patient showed positive trends across subjective tests, reported symptoms, and fMRI. Two patients had stable symptoms and fMRI responses; one improved on subjective tests, and another worsened slightly. Another patient improved in visual field tests despite worsening symptoms and fMRI trends.
Conclusion: fMRI may offer a valuable objective measure of visual functions in LHON and appears to be more relevant in assessing symptoms. Further research with more participants is needed to ascertain fMRI's role in developing objective visual assessments and treatment evaluation.
Keywords: Functional MRI; Idebenone; Leber’s hereditary optic neuropathy; Objective visual function; Primary visual cortex.
© 2024. Japanese Ophthalmological Society.
Similar articles
-
Visual function in chronic Leber's hereditary optic neuropathy during idebenone treatment initiated 5 to 50 years after onset.Graefes Arch Clin Exp Ophthalmol. 2019 Dec;257(12):2751-2757. doi: 10.1007/s00417-019-04444-6. Epub 2019 Sep 3. Graefes Arch Clin Exp Ophthalmol. 2019. PMID: 31482278
-
Idebenone vs. rAAV2-ND4 gene therapy in the treatment of Leber's hereditary optic neuropathy: An indirect comparison meta-analysis.Indian J Ophthalmol. 2025 May 1;73(5):656-664. doi: 10.4103/IJO.IJO_2898_23. Epub 2025 Apr 24. Indian J Ophthalmol. 2025. PMID: 40272293 Free PMC article.
-
Therapeutic Effects of Idebenone on Leber Hereditary Optic Neuropathy.Curr Eye Res. 2020 Oct;45(10):1315-1323. doi: 10.1080/02713683.2020.1736307. Epub 2020 Mar 9. Curr Eye Res. 2020. PMID: 32111141
-
Characteristics of Japanese patients with Leber's hereditary optic neuropathy and idebenone trial: a prospective, interventional, non-comparative study.Jpn J Ophthalmol. 2021 Jan;65(1):133-142. doi: 10.1007/s10384-020-00789-2. Epub 2020 Nov 13. Jpn J Ophthalmol. 2021. PMID: 33185792
-
Idebenone for Leber's hereditary optic neuropathy.Drugs Today (Barc). 2016 Mar;52(3):173-81. doi: 10.1358/dot.2016.52.3.2463564. Drugs Today (Barc). 2016. PMID: 27186591 Review.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical